Medical technologies

Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. Integrated with the world’s leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF). CE Mark follows recent approval of the VARIPULSE™ Platform in Japan.

Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation 

Studies Published in The Journal of Arthroplasty Feature Consensus from 20 Orthopaedic Surgeons on Surgical Wound Management with the Goal to Reduce Variability and Promote Standardization

Next-generation intermediate catheter, CEREGLIDE™ 71 Intermediate Catheter with TruCourse™, now available across the U.S.

Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months in patients with optimal Pulsed Field Ablation applications First look results from admIRE study suggests similar outcomes

Retrospective Analysis of Real-World Data Presented as Late-Breaker at 29th Annual International AF Symposium

First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world’s leading CARTO™ 3D cardiac mapping system for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib) First and only PFA system approved in Japan

Addition of hemostatic patch complements Ethicon’s comprehensive Biosurgery portfolio and ability to address critical unmet needs in controlling bleeding.